Cancer Immune Therapy: Prognostic Significance and Implications for Therapy of PD-1 in BCG-Relapsing Bladder Cancer.
作者信息
Mukherjee Neelam, Svatek Robert
机构信息
Department of Urology, Division of Urologic Oncology, University of Texas Health San Antonio (UTHSA), San Antonio, TX, USA.
出版信息
Ann Surg Oncol. 2018 Sep;25(9):2498-2499. doi: 10.1245/s10434-018-6610-7. Epub 2018 Jul 3.
Abstract
摘要
相似文献
1
Cancer Immune Therapy: Prognostic Significance and Implications for Therapy of PD-1 in BCG-Relapsing Bladder Cancer.癌症免疫疗法：PD-1在卡介苗复发膀胱癌中的预后意义及对治疗的启示
Ann Surg Oncol. 2018 Sep;25(9):2498-2499. doi: 10.1245/s10434-018-6610-7. Epub 2018 Jul 3.
2
Clinical Role of Programmed Cell Death-1 Expression in Patients with Non-muscle-invasive Bladder Cancer Recurring After Initial Bacillus Calmette-Guérin Therapy.程序性细胞死亡受体-1 表达在卡介苗治疗初始后复发的非肌肉浸润性膀胱癌患者中的临床作用。
Ann Surg Oncol. 2018 Aug;25(8):2484-2491. doi: 10.1245/s10434-018-6498-2. Epub 2018 May 1.
3
Management of BCG failures in superficial bladder cancer: a review.浅表性膀胱癌中卡介苗治疗失败的管理：综述
Eur Urol. 2006 May;49(5):790-7. doi: 10.1016/j.eururo.2006.01.017. Epub 2006 Jan 24.
4
The role of neural precursor cell-expressed developmentally down-regulated protein 9 in predicting bacillus Calmette-Guerin response in nonmuscle invasive bladder cancer.神经前体细胞表达的发育下调蛋白9在预测非肌层浸润性膀胱癌卡介苗反应中的作用
Urol Oncol. 2018 May;36(5):242.e9-242.e14. doi: 10.1016/j.urolonc.2018.02.002. Epub 2018 Mar 5.
5
Intravesical bacille Calmette-Guérin (BCG) in immunologically compromised patients with bladder cancer.免疫功能低下的膀胱癌患者膀胱内卡介苗。
BJU Int. 2013 May;111(6):984-7. doi: 10.1111/j.1464-410X.2012.11778.x. Epub 2013 Jan 25.
6
Prognostic significance of Bacillus Calmette-Guérin failure classification in non-muscle-invasive bladder cancer.卡介苗失败分类对非肌肉浸润性膀胱癌的预后意义。
BJU Int. 2012 Sep;110(6 Pt B):E216-21. doi: 10.1111/j.1464-410X.2011.10894.x. Epub 2012 Feb 7.
7
Letter: intravesical Bacille Calmette-Guerin (BCG) in immunologically compromised patients with bladder cancer--reply.信函：卡介苗（BCG）膀胱灌注治疗免疫功能低下的膀胱癌患者——回复
BJU Int. 2013 Dec;112(8):E435. doi: 10.1111/bju.12432.
8
Management of BCG "Failures".卡介苗“接种失败”的管理
Eur Urol. 2006 May;49(5):779-80. doi: 10.1016/j.eururo.2006.03.006. Epub 2006 Mar 20.
9
Prognostic significance of Nestin expression in pT1 high- grade bladder urothelial carcinoma patients treated with intravesical BCG.
Asian Pac J Cancer Prev. 2014;15(24):10813-7. doi: 10.7314/apjcp.2014.15.24.10813.
10
Management of the first recurrence of T1G3 bladder cancer: does intravesical chemotherapy deserve a chance?
Urol Oncol. 2009 May-Jun;27(3):322-4. doi: 10.1016/j.urolonc.2008.10.027.
引用本文的文献
1
A Double-Humanized Murine Model in Bladder Cancer: A Novel Preclinical Model for Cancer Immunology Research.一种膀胱癌双人源化小鼠模型：癌症免疫学研究的新型临床前模型。
Cancer Med. 2025 Aug;14(15):e71150. doi: 10.1002/cam4.71150.
2
Perioperative Immune Checkpoint Blockade for Muscle-Invasive and Metastatic Bladder Cancer.肌肉浸润性和转移性膀胱癌的围手术期免疫检查点阻断
J Cancer Immunol (Wilmington). 2024;6(1):29-39. doi: 10.33696/cancerimmunol.6.081.
3
Metabolomic Signatures of Treatment Response in Bladder Cancer.膀胱癌治疗反应的代谢组学特征。
Int J Mol Sci. 2023 Dec 16;24(24):17543. doi: 10.3390/ijms242417543.
4
Targeted therapies in bladder cancer: signaling pathways, applications, and challenges.膀胱癌的靶向治疗：信号通路、应用及挑战
MedComm (2020). 2023 Dec 15;4(6):e455. doi: 10.1002/mco2.455. eCollection 2023 Dec.
5
Innate Lymphoid Cells in Bladder Cancer: From Mechanisms of Action to Immune Therapies.先天性淋巴细胞在膀胱癌中的作用：从作用机制到免疫治疗。
Cancer Immunol Res. 2024 Feb 2;12(2):149-160. doi: 10.1158/2326-6066.CIR-23-0414.
本文引用的文献
1
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.PD-1 表达与 B 细胞淋巴瘤的临床 PD-1 阻断
Blood. 2018 Jan 4;131(1):68-83. doi: 10.1182/blood-2017-07-740993. Epub 2017 Nov 8.
2
Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer.一旦对卡介苗无反应，永远对卡介苗无反应：致美国食品药品监督管理局的一封公开信，呼吁加强膀胱癌临床试验的受试者招募工作
Bladder Cancer. 2017 Jul 27;3(3):145-146. doi: 10.3233/BLC-170118.
3
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.肿瘤中 PD-L2 的表达：与癌症抗 PD-1 治疗的相关性。
Clin Cancer Res. 2017 Jun 15;23(12):3158-3167. doi: 10.1158/1078-0432.CCR-16-1761.
4
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.T细胞共刺激受体CD28是PD-1介导抑制作用的主要靶点。
Science. 2017 Mar 31;355(6332):1428-1433. doi: 10.1126/science.aaf1292. Epub 2017 Mar 9.
5
PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.非小细胞肺癌中PD-1、PD-L1蛋白表达及其与肿瘤浸润淋巴细胞的关系
Med Sci Monit. 2017 Mar 9;23:1208-1216. doi: 10.12659/msm.899909.
6
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.抗程序性细胞死亡配体-1免疫检查点抑制剂度伐利尤单抗（MEDI4736）在晚期尿路上皮膀胱癌患者中的安全性和有效性
J Clin Oncol. 2016 Sep 10;34(26):3119-25. doi: 10.1200/JCO.2016.67.9761. Epub 2016 Jun 6.
7
T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment.T细胞在急性髓系白血病（AML）中功能未受损：仅在复发时观察到程序性死亡受体1（PD-1）表达增加，且与向记忆性T细胞亚群的转变相关。
J Hematol Oncol. 2015 Jul 30;8:93. doi: 10.1186/s13045-015-0189-2.
8
Factors affecting immunoreactivity in long-term storage of formalin-fixed paraffin-embedded tissue sections.影响福尔马林固定石蜡包埋组织切片长期储存中免疫反应性的因素。
Histochem Cell Biol. 2015 Jul;144(1):93-9. doi: 10.1007/s00418-015-1316-4. Epub 2015 Mar 11.
9
Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.免疫检查点阻断免疫疗法激活抗肿瘤 T 细胞免疫。
Br J Haematol. 2013 Aug;162(3):313-25. doi: 10.1111/bjh.12380. Epub 2013 May 21.
10
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.程序性细胞死亡蛋白 1 形成负性共刺激微簇，通过募集磷酸酶 SHP2 直接抑制 T 细胞受体信号转导。
J Exp Med. 2012 Jun 4;209(6):1201-17. doi: 10.1084/jem.20112741. Epub 2012 May 28.
Zotero 插件